Merging pharmacometabolomics with pharmacogenomics using '1000 Genomes' single-nucleotide polymorphism imputation: Selective serotonin reuptake inhibitor response pharmacogenomics

Pharmacogenetics and Genomics

Volumn 22, Issue 4, 2012, Pages 247-253

  Abo, Ryan ^a   Hebbring, Scott ^a   Ji, Yuan ^a   Zhu, Hongjie ^c   Zeng, Zhao Bang ^c   Batzler, Anthony ^b   Jenkins, Gregory D ^b   Biernacka, Joanna ^b   Snyder, Karen ^b   Drews, Maureen ^b   Fiehn, Oliver ^e   Fridley, Brooke ^b   Schaid, Daniel ^b   Kamatani, Naoyuki ^f   Nakamura, Yusuke ^f   Kubo, Michiaki ^f   Mushiroda, Taisei ^f   Kaddurah Daouk, Rima ^d   Mrazek, David A ^b   Weinshilboum, Richard M ^a  

^a MAYO GRADUATE SCHOOL   (United States)

^b MAYO CLINIC   (United States)

^c NORTH CAROLINA STATE UNIVERSITY   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f RIKEN   (Japan)

Author keywords

1000 Genomes; HapMap; imputation; major depressive disorder; pharmacogenomics; pharmacometabolomics; selective serotonin reuptake inhibitors; tag single nucleotide polymorphisms

Indexed keywords

CITALOPRAM; DNA; ESCITALOPRAM; GLYCINE; GLYCINE DEHYDROGENASE;

AMINO ACID SYNTHESIS; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DRUG METABOLISM; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC CODE; GENETIC MARKER; GENOTYPE; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; METABOLOMICS; PHARMACOGENOMICS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84863413686     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32835001c9     Document Type: Article

References (12)

1. Sorger PK, Allerheiligen SRB, Abernethy DR, Altman RB, Brouwer KLR, Califano A, et al. Quantitative and systems pharmacology in the post-genomic era: new approaches to discovering drugs and understanding therapeutic mechanisms. Ward Reds QSP Workshop Group; 2011. Available at [http://www.nigms.nih.gov/NR/rdonlyres/8ECB1F7C-BE3B-431F-89E6-A43411811AB1/0/ SystemsPharmaWPSorger2011.pdf].
2. Kaddurah-Daouk R, Kristal BS, Weinshilboum RM. Metabolomics: aglobal biochemical approach to drug response and disease. Annu Rev Pharmacol Toxicol 2008; 48:653-683. (Pubitemid 351738167)
3. Ji Y, Hebbring S, Zhu H, Jenkins GD, Biernacka J, Snyder K, et al. Glycine and aglycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics. Clin Pharmacol Ther 2011; 89:97-104.
4. Durbin RM, Altshuler DL, Abecasis GR, Bentley DR, Chakravarti A, Clark AG, et al. A map ofhuman genome variation from population-scale sequencing. Nature 2010; 467:1061-1073.
5. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003; 54:573-583. (Pubitemid 37289444)
6. Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR. MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet Epidemiol 2010; 34:816-834.
7. Biernacka JM, Tang R, Li J, McDonnell SK, Rabe KG, Sinnwell JP, et al. Assessment of genotype imputation methods. BMC Proceedings 2009; 3 (Suppl 7):S5.
8. Nothnagel M, Ellinghaus D, Schreiber S, Krawczak M, Franke A. A comprehensive evaluation ofSNP genotype imputation. Human Genet 2009; 125:163-171.
9. Pritchard JK, Stephens M, Donnelly P. Inference ofpopulation structure using multilocus genotype data. Genetics 2000; 155:945-959. (Pubitemid 30397141)
10. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nature Genet 2006; 38:904-909. (Pubitemid 44141658)
11. Michel S, Liang L, Depner M, Klopp N, Ruether A, Kumar A, et al. Unifying candidate gene and GWAS approaches in asthma. PLoS ONE 2010; 5:e13894.
12. Orho-Melander M, Melander O, Guiducci C, Perez-Martinez P, Corella D, Roos C, et al. Common missense variant inthe glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations. Diabetes 2008; 57:3112-3121.